(AMWL) American Well - Ratings and Ratios
Telehealth Platform, Virtual Consultations, Healthcare Software
AMWL EPS (Earnings per Share)
AMWL Revenue
Description: AMWL American Well
American Well Corp (NYSE:AMWL) is a US-based company operating in the Health Care Equipment sub-industry. The companys quarterly tax provision indicates a need for scrutiny of its financial performance.
To assess the companys viability, we need to examine key performance indicators (KPIs) such as revenue growth, customer acquisition costs, and operating expenses. The negative Return on Equity (RoE) of -40.89% suggests significant losses, potentially due to high operating expenses or investments in growth initiatives.
The companys market capitalization stands at $117.59M, indicating a relatively small-cap stock with potential for volatility. The absence of a reported P/E ratio and forward P/E ratio may be due to negative earnings, which could be a result of significant investments in research and development, sales and marketing, or other growth drivers.
Key economic drivers for American Well Corp include the growing demand for telemedicine services, the shift towards value-based healthcare, and the increasing adoption of digital health technologies. The companys ability to capitalize on these trends will be crucial in driving future growth and improving its financial performance.
To engineer a solution, we need to identify leverage points, such as optimizing the companys cost structure, improving its sales and marketing efficiency, or investing in high-growth areas like AI-powered healthcare platforms. By prioritizing initiatives based on their impact-to-effort ratio, American Well Corp can potentially improve its financial performance and create value for shareholders.
AMWL Stock Overview
| Market Cap in USD | 111m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2020-09-17 |
AMWL Stock Ratings
| Growth Rating | -85.3% |
| Fundamental | 20.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -42.2% |
| Analyst Rating | 3.22 of 5 |
AMWL Dividends
Currently no dividends paidAMWL Growth Ratios
| Growth Correlation 3m | -57.6% |
| Growth Correlation 12m | -68% |
| Growth Correlation 5y | -97.8% |
| CAGR 5y | -56.17% |
| CAGR/Max DD 3y | -0.60 |
| CAGR/Mean DD 3y | -0.71 |
| Sharpe Ratio 12m | -1.55 |
| Alpha | 0.09 |
| Beta | 0.785 |
| Volatility | 66.97% |
| Current Volume | 23.9k |
| Average Volume 20d | 41.7k |
| Stop Loss | 6.2 (-5.1%) |
| Signal | -1.17 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-124.5m TTM) > 0 and > 6% of Revenue (6% = 16.2m TTM) |
| FCFTA -0.37 (>2.0%) and ΔFCFTA -4.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 74.78% (prev 101.2%; Δ -26.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -75.6m > Net Income -124.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.9m) change vs 12m ago 6.84% (target <= -2.0% for YES) |
| Gross Margin 48.97% (prev 27.72%; Δ 21.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 60.19% (prev 50.20%; Δ 9.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -29.81 (EBITDA TTM -108.4m / Interest Expense TTM 4.73m) >= 6 (WARN >= 3) |
Altman Z'' -38.04
| (A) 0.52 = (Total Current Assets 289.7m - Total Current Liabilities 87.9m) / Total Assets 388.7m |
| (B) -5.16 = Retained Earnings (Balance) -2.00b / Total Assets 388.7m |
| warn (B) unusual magnitude: -5.16 — check mapping/units |
| (C) -0.31 = EBIT TTM -140.9m / Avg Total Assets 448.2m |
| (D) -21.45 = Book Value of Equity -2.02b / Total Liabilities 94.1m |
| Total Rating: -38.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 20.62
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin -52.84% = -7.50 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda -0.09 = -2.50 |
| 6. ROIC - WACC (= -55.01)% = -12.50 |
| 7. RoE -40.89% = -2.50 |
| 8. Rev. Trend -11.74% = -0.88 |
| 9. EPS Trend -70.01% = -3.50 |
What is the price of AMWL shares?
Over the past week, the price has changed by -4.95%, over one month by -9.93%, over three months by -5.77% and over the past year by -31.34%.
Is American Well a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMWL is around 3.04 USD . This means that AMWL is currently overvalued and has a potential downside of -53.45%.
Is AMWL a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AMWL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.5 | 45.5% |
| Analysts Target Price | 9.5 | 45.5% |
| ValueRay Target Price | 3.4 | -47.9% |
Last update: 2025-09-11 04:31
AMWL Fundamental Data Overview
CCE Cash And Equivalents = 219.1m USD (Cash And Short Term Investments, last quarter)
P/S = 0.4113
P/B = 0.3927
Beta = 1.282
Revenue TTM = 269.8m USD
EBIT TTM = -140.9m USD
EBITDA TTM = -108.4m USD
Long Term Debt = 6.17m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.70m USD (from shortTermDebt, last quarter)
Debt = 9.87m USD (Calculated: Short Term 3.70m + Long Term 6.17m)
Net Debt = -212.7m USD (from netDebt column, last quarter)
Enterprise Value = -98.2m USD (111.0m + Debt 9.87m - CCE 219.1m)
Interest Coverage Ratio = -29.81 (Ebit TTM -140.9m / Interest Expense TTM 4.73m)
FCF Yield = -145.1% (FCF TTM -142.6m / Enterprise Value -98.2m)
FCF Margin = -52.84% (FCF TTM -142.6m / Revenue TTM 269.8m)
Net Margin = -46.15% (Net Income TTM -124.5m / Revenue TTM 269.8m)
Gross Margin = 48.97% ((Revenue TTM 269.8m - Cost of Revenue TTM 137.7m) / Revenue TTM)
Tobins Q-Ratio = 0.05 (Enterprise Value -98.2m / Book Value Of Equity -2.02b)
Interest Expense / Debt = 8.56% (Interest Expense 845.0k / Debt 9.87m)
Taxrate = 21.0% (US default)
NOPAT = -140.9m (EBIT -140.9m, no tax applied on loss)
Current Ratio = 3.29 (Total Current Assets 289.7m / Total Current Liabilities 87.9m)
Debt / Equity = 0.03 (Debt 9.87m / last Quarter total Stockholder Equity 282.6m)
Debt / EBITDA = -0.09 (Net Debt -212.7m / EBITDA -108.4m)
Debt / FCF = -0.07 (Debt 9.87m / FCF TTM -142.6m)
Total Stockholder Equity = 304.5m (last 4 quarters mean)
RoA = -32.04% (Net Income -124.5m, Total Assets 388.7m )
RoE = -40.89% (Net Income TTM -124.5m / Total Stockholder Equity 304.5m)
RoCE = -45.36% (Ebit -140.9m / (Equity 304.5m + L.T.Debt 6.17m))
RoIC = -46.28% (NOPAT -140.9m / Invested Capital 304.5m)
WACC = 8.73% (E(111.0m)/V(120.8m) * Re(8.91%)) + (D(9.87m)/V(120.8m) * Rd(8.56%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.25%
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -142.6m)
EPS Correlation: -70.01 | EPS CAGR: -12.82% | SUE: 1.15 | # QB: 5
Revenue Correlation: -11.74 | Revenue CAGR: 0.88%
Additional Sources for AMWL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle